BCR and neoplasm: Consistent with the previously reported tumour-suppressor role of PP2A, its activating drugs, such as FTY720 and OP449, have been shown to re-sensitize TKI-resistant LSCs to BCR::ABL1 inhibition by targeting the JAK2/PP2A/β-catenin pathway (Figure 3 and Table 2) [105].